Tsukada Hideo, Sato Kengo, Fukumoto Dai, Nishiyama Shingo, Harada Norihiro, Kakiuchi Takeharu
PET Center, Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, Shizuoka 434-8601, Japan.
J Nucl Med. 2006 Apr;47(4):679-88.
The aim of this study was to investigate whether D-amino acid isomers of O-(11)C-methyl tyrosine ((11)C-CMT) and O-(18)F-fluoromethyl tyrosine ((18)F-FMT) were better than the corresponding L-isomers as tumor- detecting agents with PET in comparison with the difference between L- and D-methyl-(11)C-methionine ((11)C-MET).
L- and D-(11)C-MET, (11)C-CMT, and (18)F-FMT were injected intravenously into BALB/cA Jcl-nu mice bearing HeLa tumor cells. At 5, 15, 30, and 60 min after injection, normal abdominal organs and xenotransplanted HeLa cells were sampled, and the uptake of each ligand was determined. Metabolic analyses of these compounds in the plasma were also performed. Accumulation of the d-isomers of (11)C-MET, (11)C-CMT, and (18)F-FMT in turpentine-induced inflammatory tissue was assayed in comparison with (18)F-FDG. The whole-body distribution of each tracer was imaged with a planar positron imaging system (PPIS).
Although the tumor uptake (standardized uptake value [SUV]) levels of the D-isomers of (11)C-MET, (11)C-CMT, and (18)F-FMT were 261%, 72%, and 95% of each L-isomer 60 min after administration, the tumor-to-blood ratios of these D-isomers were 130%, 140%, and 182% of the corresponding L-isomers. In the blood, the D-isomers of these labeled compounds revealed a relatively faster elimination rate compared with their L-isomers, with a high peak uptake in the blood and kidney 5 min after administration. Compared with the natural amino acid ligand l-(11)C-MET, the uptake of L-isomers of (11)C-CMT and (18)F-FMT was relatively low and stable in the abdominal organs, whereas D-isomers revealed much lower levels and faster clearance rates compared with corresponding L-isomers. Among the abdominal organs, the pancreas showed a relatively high uptake of (11)C-CMT and (18)F-FMT; the uptake of these D-isomers was much lower than that of L-isomers. Pretreatment with cycloheximide, a protein synthesis inhibitor, resulted in a marked reduction of L-(11)C-MET uptake and a slight reduction of D-(11)C-MET uptake into protein fractions, whereas no significant changes were detected with L- and D-(11)C-CMT and (18)F-FMT. D-Isomers of (11)C-MET, (11)C-CMT, and (18)F-FMT did not accumulate in turpentine-induced inflammatory tissue, where (18)F-FDG revealed a high uptake. Whole-body imaging with a PPIS provided consistent distribution data obtained from the tissue dissection analysis.
These results suggest that D-isomers of (11)C-CMT and (18)F-FMT could be potentially better tracers than L- and D-(11)C-MET for tumor imaging with PET.
本研究的目的是调查O-(11)C-甲基酪氨酸((11)C-CMT)和O-(18)F-氟甲基酪氨酸((18)F-FMT)的D-氨基酸异构体作为正电子发射断层扫描(PET)肿瘤检测剂是否优于相应的L-异构体,并比较L-和D-甲基-(11)C-蛋氨酸((11)C-MET)之间的差异。
将L-和D-(11)C-MET、(11)C-CMT和(18)F-FMT静脉注射到携带人宫颈癌HeLa细胞的BALB/cA Jcl-nu小鼠体内。在注射后5、15、30和60分钟,采集正常腹部器官和异种移植的HeLa细胞,测定每种配体的摄取情况。还对这些化合物在血浆中的代谢进行了分析。与(18)F-FDG相比,测定了(11)C-MET、(11)C-CMT和(18)F-FMT的d-异构体在松节油诱导的炎症组织中的蓄积情况。使用平面正电子成像系统(PPIS)对每种示踪剂的全身分布进行成像。
尽管给药60分钟后,(11)C-MET、(11)C-CMT和(18)F-FMT的D-异构体的肿瘤摄取(标准化摄取值[SUV])水平分别为各自L-异构体的261%、72%和95%,但这些D-异构体的肿瘤与血液比值分别为相应L-异构体的130%、140%和182%。在血液中,这些标记化合物的D-异构体与它们的L-异构体相比,显示出相对较快的消除率,给药后5分钟在血液和肾脏中摄取达到高峰。与天然氨基酸配体L-(11)C-MET相比,(11)C-CMT和(18)F-FMT的L-异构体在腹部器官中的摄取相对较低且稳定,而D-异构体与相应的L-异构体相比,水平更低且清除率更快。在腹部器官中,胰腺对(11)C-CMT和(18)F-FMT的摄取相对较高;这些D-异构体的摄取远低于L-异构体。用蛋白质合成抑制剂环己酰亚胺预处理导致L-(11)C-MET摄取显著降低,D-(11)C-MET摄取到蛋白质组分中略有降低,而L-和D-(11)C-CMT以及(18)F-FMT未检测到显著变化。(11)C-MET、(11)C-CMT和(18)F-FMT的D-异构体在松节油诱导的炎症组织中不蓄积,而(18)F-FDG在该组织中摄取较高。使用PPIS进行的全身成像提供了与组织解剖分析一致的分布数据。
这些结果表明,对于PET肿瘤成像,(11)C-CMT和(18)F-FMT的D-异构体可能比L-和D-(11)C-MET更适合作为示踪剂。